clairop

Which Biologic Is Best for Crohn's Disease?

No biologic is best for everyone. How the classes compare in network meta-analyzes and AGA, ACG and ECCO guidance, and what to ask your GI.

Clairop Team20 min read

Photo: Arphy / Unsplash

The short answer

No single biologic is best for every person with Crohn's disease. Network meta-analyzes and the 2025 AGA guideline rank classes by whether you have had an advanced therapy before, and head-to-head trials found ustekinumab and adalimumab similar in biologic-naive disease. Perianal fistulas, past anti-TNF use, safety, route and insurance rules all shape the choice with your gastroenterologist.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

No single biologic is best for every person with Crohn's disease. A biologic is a lab-made antibody that blocks one part of the immune pathway driving gut inflammation, and the 2025 American Gastroenterological Association (AGA) guideline recommends several of them as comparable first-line choices. Which one fits you depends on whether you have had an advanced therapy before, whether you have perianal fistulas, how you weigh safety and convenience, and what your insurer will approve. This article compares the classes using network meta-analyzes, head-to-head trials and guidelines, and it does not tell you to start, stop or switch anything. Every choice here belongs to you and your gastroenterologist.

If you already have a biologic and are wondering about a change, see our guide on how often people switch biologics for Crohn's. This page is about the earlier question: how to think about the options when the decision is in front of you.

Which biologic is best for Crohn's disease?

There is no universally best biologic. The 2025 AGA living guideline, built on a network meta-analysis of 28 induction trials and 22 maintenance trials, recommends seven advanced therapies over no treatment and ranks them in groups, not in a single order (Scott 2025; Singh 2025). Individual response varies, so the practical question is which option fits your disease and your life. For drug-by-drug timelines, see how long Crohn's biologics take to work.

Crohn's disease is a lifelong inflammatory bowel disease in which the immune system inflames the wall of the digestive tract. "Biologic" usually covers antibodies against tumor necrosis factor (anti-TNF drugs such as infliximab and adalimumab), against gut-homing immune cells (vedolizumab), against interleukins 12 and 23 (ustekinumab) and against interleukin 23 only (risankizumab, guselkumab and mirikizumab). Upadacitinib, a Janus kinase (JAK) inhibitor, is a daily pill rather than a biologic, but it appears in the same guidelines under "advanced therapies", so this article covers it too.

People on r/CrohnsDisease often ask this exact question and get a mix of loyalty and caution. In one thread asking which biologic to choose, replies described very different experiences, with a drug that failed one person praised by another. That is consistent with the trial data: averages favor groups of drugs, and individuals scatter around them.

What do the guidelines say about choosing a biologic?

The AGA suggests a higher-efficacy drug (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab or guselkumab) over a lower-efficacy one (certolizumab pegol or upadacitinib) for people who have never had an advanced therapy (Scott 2025). It also suggests starting with an advanced therapy rather than stepping up through steroids or immunomodulators first.

The same guideline gives a different list for people who have been exposed to one or more advanced therapies: higher efficacy for adalimumab, risankizumab, guselkumab or upadacitinib, intermediate for ustekinumab or mirikizumab, and lower for vedolizumab or certolizumab pegol. It suggests combining infliximab with a thiopurine rather than using infliximab alone, particularly in people who have not had a thiopurine, and it flags several areas as knowledge gaps because evidence is thin.

The American College of Gastroenterology (ACG) guideline from 2025 covers the same ground for adults and states plainly that shared decision-making with the patient is advocated, and that its recommendations are meant to be flexible and not the only acceptable approach (Lichtenstein 2025). The European Crohn's and Colitis Organisation (ECCO) published its own 2024 guideline on medical treatment of Crohn's disease (Gordon 2024). This article does not summarize its individual recommendations, so if you live in Europe, ask your team how it applies locally.

How do the drug classes compare?

The classes differ in target, route and evidence. The table below summarizes the pivotal trials and labels we opened for this article. Percentages come from different trials with different patients and endpoints, so they are not a ranking and should not be compared across rows.

Class (examples)TargetHow it is given (per trial or label)Anchor evidenceBoxed warning in current US label
Anti-TNF (infliximab, adalimumab)Tumor necrosis factorInfliximab by infusion, with a subcutaneous infliximab product labeled for maintenance after IV treatment; adalimumab by injectionInfliximab with azathioprine reached steroid-free remission in 56.8% at week 26 versus 44.4% for infliximab alone and 30.0% for azathioprine alone (SONIC)Yes: serious infections and malignancy
Anti-integrin (vedolizumab)Gut-homing integrinInfusion in the pivotal trialWeek 6 remission 14.5% vs 6.8% on placebo; week 52 remission 39.0% (every 8 weeks) vs 21.6% among respondersNone found in the label we opened
IL-12/23 (ustekinumab)p40 subunitSingle IV dose, then injectionsWeek 44 remission 53.1% (every 8 weeks) vs 35.9% on placebo among respondersNone found in the label we opened
IL-23 (risankizumab, guselkumab, mirikizumab)p19 subunitIV induction in the risankizumab trials, then injections; check each labelRisankizumab: week 12 CDAI remission 45% vs 25% on placebo in ADVANCENone found in the labels we opened
JAK inhibitor (upadacitinib)Janus kinaseDaily pillWeek 12 remission 49.5% vs 29.1% in U-EXCELYes: serious infections, mortality, malignancy, cardiovascular events, thrombosis

Sources for the table: Colombel 2010, Sandborn 2013, Feagan 2016, D'Haens 2022, Loftus 2023 and the DailyMed labels for Remicade, Humira, Zymfentra and Rinvoq. Guselkumab and mirikizumab are included in the AGA recommendations above, and their labels and trials should be checked directly with your prescriber.

Two caveats matter when reading the table. First, trials enrolled different groups: UNITI-1 enrolled people whose anti-TNF had failed, UNITI-2 people who had failed conventional therapy, and the SONIC population had not had immunosuppressants or biologics. Second, "remission" was defined by the Crohn's Disease Activity Index (CDAI) in these trials, a score built from symptoms and exam findings. Endoscopic outcomes, which look at the bowel lining, are reported separately and often come out lower.

Has any head-to-head trial settled which is better?

Only a few exist. In SEAVUE, which enrolled 386 biologic-naive people, week-52 clinical remission was 65% with ustekinumab and 61% with adalimumab, a difference that was not statistically significant (Sands 2022). In SEQUENCE, risankizumab beat ustekinumab on endoscopic remission after an anti-TNF.

SEAVUE was randomized and double-blind, and both drugs were given as monotherapy without dose changes. Serious infections occurred in 2% of the ustekinumab group and 3% of the adalimumab group, and no deaths occurred through week 52. The trial tells you that two common first choices performed similarly on average in this population. It does not say that either would work for you, or how they compare with infliximab, which was not in the trial.

SEQUENCE enrolled people with moderate-to-severe Crohn's who had an inadequate response to, or side effects from, an anti-TNF. Risankizumab was non-inferior to ustekinumab for clinical remission at week 24 (58.6% vs 39.5%) and superior for endoscopic remission at week 48 (31.8% vs 16.2%) (Peyrin-Biroulet 2024). Read that result with care. The study was open label with blinded assessment of endpoints, and AbbVie, which makes risankizumab, funded it. Adverse events appeared similar in both groups.

The honest summary is that head-to-head evidence is thin. Most comparisons between drugs rely on network meta-analyzes, which compare drugs indirectly through their placebo arms and carry more uncertainty than a direct trial. The AGA's version graded certainty and found moderate-to-high certainty for several comparisons and low for others (Singh 2025).

Does it matter if you have already had an anti-TNF?

Yes, it is one of the main factors. In the network meta-analysis, biologic-naive patients had moderate-to-high certainty evidence of benefit for infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab and guselkumab. After a prior biologic, the comparison between active drugs favored risankizumab and guselkumab over vedolizumab and ustekinumab with moderate certainty (Singh 2025).

In biologic-naive people, the same analysis found moderate-to-high certainty that adalimumab and ustekinumab were better than certolizumab pegol and upadacitinib for inducing remission. For people with prior biologic exposure, it found moderate-to-high certainty for adalimumab, ustekinumab, risankizumab, guselkumab and upadacitinib over no treatment, and only low certainty for vedolizumab and mirikizumab.

This is why the first-line question and the second-line question have different answers. A person whose first anti-TNF stopped working is not choosing from the same table as someone starting from scratch. Our guide on what it means when a biologic stops working explains why response fades and what your team checks, and what to do when all biologics fail covers the later stages.

The trial data back the same pattern. In UNITI-1, which enrolled people who had stopped responding to or could not tolerate an anti-TNF, week-6 response was 34.3% on the lower ustekinumab dose and 33.7% on the higher dose versus 21.5% on placebo (Feagan 2016). In ADVANCE, risankizumab's CDAI remission at week 12 was 45% versus 25% on placebo, and endoscopic response was 40% versus 12% (D'Haens 2022). In the FORTIFY maintenance study, endoscopic response at week 52 was 47% on risankizumab 360 mg versus 22% on withdrawal to placebo (Ferrante 2022). These trials included people with prior biologic exposure but were not designed to compare the drugs against each other.

What if you have perianal fistulas?

Perianal fistulas are a special case, and infliximab has the deepest evidence. In the first randomized trial, 68% on infliximab 5 mg/kg had a 50% or greater reduction in draining fistulas versus 26% on placebo, and 55% had all fistulas close versus 13% (Present 1999). In ACCENT II, 36% on maintenance infliximab had no draining fistulas at week 54 versus 19% on placebo (Sands 2004).

A 2026 meta-analysis of placebo-controlled trials pooled 14 studies, only 4 of which were designed for perianal Crohn's disease. The rest were post hoc analyzes of luminal trials with moderate to serious risk of bias. It concluded that infliximab is effective for perianal Crohn's disease, with limited evidence of benefit with adalimumab, ustekinumab and upadacitinib (Yuan 2026). That is a statement about the strength of evidence, not proof that the other drugs do not work.

Fistulas also usually need more than medicine. Surgeons and radiologists often map the tracts with MRI and treat abscesses before or alongside drug therapy. If you are living with a fistula and want to understand what it can feel like, what a perianal fistula feels like describes the common symptoms. In r/CrohnsDisease, people with perianal disease often describe medical evidence and coverage rules pulling in different directions, so ask your team about both.

Which biologic is the safest?

None is risk free, and no single agent is clearly the safest on current evidence. The labels for infliximab and adalimumab carry boxed warnings for serious infections and malignancy, and upadacitinib's label adds mortality, major cardiovascular events and thrombosis (Remicade label; Humira label; Rinvoq label).

A 2026 retrospective claims study of 12,245 commercially insured people with Crohn's disease compared anti-TNF drugs, vedolizumab, ustekinumab, risankizumab and upadacitinib. Serious infection rates ranged from 5.46 to 9.02 per 100 person-years across therapies, and after adjustment there were no statistically significant differences in serious infections, venous thromboembolism or major cardiovascular events. The authors concluded that choice could be driven mainly by effectiveness for most people (Park 2026).

Limits apply. The study was observational, which means unmeasured differences between groups can remain, and only 152 people took upadacitinib and 559 took risankizumab, so smaller differences could be missed. In the pivotal trials we opened, vedolizumab had a higher rate of serious infections than placebo in GEMINI 2 (5.5% vs 3.0%), and upadacitinib had more herpes zoster than placebo (Sandborn 2013; Loftus 2023). Those are trial findings against placebo, not comparisons between drugs.

Your own history matters more than a ranking. Ask your gastroenterologist how past infections, vaccination status, tuberculosis screening, age, smoking, cardiovascular risk and other conditions change the risk calculation for you specifically.

Does the way you take it matter: infusion or injection?

Route is a legitimate factor, and it is one that people in the community raise constantly. In the Humira, Remicade, Skyrizi or Tremfya thread, some people liked the idea of a quiet hour in an infusion chair every few weeks, while others preferred a home injection pen. Neither view is medical evidence, but both are real constraints on adherence and work life.

Here is what the labels and trials say about routes. Infliximab is given by intravenous infusion, and a subcutaneous infliximab product is labeled for maintenance treatment only after intravenous infliximab (Zymfentra label). Adalimumab is a subcutaneous injection. Ustekinumab and risankizumab started with intravenous induction in their trials and moved to subcutaneous maintenance (Feagan 2016; Ferrante 2022). Upadacitinib is a daily pill (Loftus 2023).

Practical points to raise with your team: how many hours infusions take, whether your workplace allows time off, how comfortable you are with self-injection, whether you travel, and how drugs are stored. For first-time infusions, what to expect at your first biologic infusion walks through the day.

What about biosimilars, insurance and prior authorization?

A biosimilar is a highly similar version of an originator biologic, usually priced lower. In NOR-SWITCH, which switched stable patients from originator infliximab to biosimilar CT-P13, 26% on the originator and 30% on the biosimilar had disease worsening over 52 weeks, within the 15-point margin set for non-inferiority, and safety was similar (Jorgensen 2017). About a third of participants had Crohn's disease.

This section is US-focused, because coverage rules are country-specific. In the US, insurers commonly use step therapy and prior authorization, which can require a preferred drug or biosimilar before approving another. We did not find a source that quantifies how often this changes which biologic someone receives, so we are not putting a number on it. It is a question to ask, not a fixed rule.

What people in r/CrohnsDisease report is consistent across threads. A common view is that infliximab, or a biosimilar, is often tried first because of insurer requirements, and that newer drugs can be harder to get approved while they are still protected by patents. One comment in the starting biologics thread says figuring out coverage is the job of the prior authorization staff at the gastroenterology office, not the patient. One commenter in Australia described needing to try one drug before another under the national scheme, while saying they were not sure of the exact rule, which is itself a sign of how confusing these rules are. These are lived-experience reports, so verify the rules for your own plan or country with your clinic.

Questions that help here: Which drugs does my plan prefer? Is a biosimilar an option for me? If a request is denied, what is the appeal process, and can you write a letter of medical necessity? Is there a manufacturer support program? You might also ask whether any step requirements can be waived because of your disease features.

One claim you will see online is that doctors only offer a choice when drugs are equivalent. We could not verify that as a general rule, and the guidelines say instead that shared decision-making is the standard. Your team will tell you where they see a clear reason to prefer one option.

How long before you know if a biologic is working?

It depends on the drug and the outcome. Pivotal trials assess response at fixed points: week 6 for ustekinumab and vedolizumab induction, week 12 for risankizumab and upadacitinib induction, and maintenance outcomes at about 44 to 52 weeks (Feagan 2016; Sandborn 2013; D'Haens 2022; Loftus 2023). Your own checkpoint is for your gastroenterologist to set.

You may read online that infliximab works fastest. We did not find head-to-head onset data in the sources we opened to support or refute that, so we leave it as a community impression. What the trials do show is that symptom response, blood and stool markers and endoscopic healing can move at different speeds, which is why a single "feel better" check is not enough. In vedolizumab's induction trial, week-6 remission was only 14.5% against 6.8% on placebo, but 39.0% of week-6 responders on every-8-week dosing were in remission at week 52 (Sandborn 2013).

How can you track whether your biologic is working?

A dated log of symptoms, side effects and results gives you and your team something concrete to judge response against. Trial evidence supports measuring more than symptoms: in CALM, adjusting treatment based on symptoms plus C-reactive protein (CRP) and fecal calprotectin led to mucosal healing without deep ulcers in 46% at week 48, against 30% with symptom-based management (Colombel 2017).

CALM enrolled people with early disease, a mean duration of about one year, and the escalation used adalimumab, so it does not translate directly to every situation. Its lesson is that objective markers catch inflammation that how you feel can miss. The international treat-to-target consensus, STRIDE-II, lists symptom relief and normalization of blood and stool markers as short-term targets, and clinical remission with endoscopic healing as long-term targets (Turner 2021).

A simple tracking routine around a new biologic might include:

  • The start date and every dose or infusion date, plus any delayed or missed dose.
  • Stool frequency and form, urgency, night-time bowel movements, blood or mucus, and pain on a 0 to 10 scale.
  • Energy, appetite, weight if your team wants it, and any fistula drainage.
  • Side effects, infections, antibiotic or steroid courses, and new joint or skin symptoms.
  • Dates and results of CRP, calprotectin, drug levels and scopes, so symptoms and numbers sit on one timeline.

Our guides on what to track in an IBD symptom diary, why you need blood tests on a biologic and whether calprotectin can be normal with Crohn's cover the pieces. A tracker such as Clairop can put symptoms, medication dates and lab entries on a single timeline that you can share with your care team, and our how it works page shows how. It does not diagnose, treat or tell you whether to change medicine, and it does not replace calprotectin, imaging or colonoscopy.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

What questions can you take to your gastroenterologist?

Good questions turn a vague worry into a useful appointment. None of the following are instructions. They are prompts for your prescriber.

  • What do my scope, imaging and stool results show, and how does that change which drug classes make sense?
  • Do I have perianal disease, strictures or other features that favor one option?
  • Have I had an advanced therapy before, and how does that change my options?
  • Which drugs does my insurance prefer, and what is the plan if a request is denied?
  • Is a biosimilar an option for me?
  • What are the main risks for me given my age, infections, vaccinations and other conditions?
  • Do I need a thiopurine or other medicine alongside it, and why?
  • How will you judge whether it is working, and when will we repeat tests?
  • What would we do if it did not work, or if I had a reaction?

For a broader list, see questions to ask your doctor about Crohn's disease. If you are earlier in the journey and wondering whether a biologic is needed at all, should you start biologics for mild Crohn's covers that decision. For one specific drug, Remicade pros and cons for Crohn's goes deeper on infliximab.

When should you see a doctor promptly?

Contact your IBD team promptly, or seek urgent care, for blood in the stool, fever, severe or worsening abdominal pain, repeated vomiting, signs of dehydration, unexplained weight loss, new or worsening perianal pain or drainage, or any sign of a serious infection while on a biologic. Do not wait for a routine appointment if symptoms change in a way that worries you.

Also call before a planned vaccination, surgery or dental procedure if you are on a biologic, and tell every clinician you see that you take one. Do not stop or skip doses because of something you read, including here, because stopping can change how well a drug works later. Our guide on how to tell if you are in a Crohn's flare covers what to watch.

Common myths about choosing a Crohn's biologic

Myth: there is a tier list, and the newest drug is always best. The AGA groups drugs by efficacy for specific situations, and the groupings change depending on prior treatment. Newer does not mean better for you, and newer drugs have shorter safety follow-up.

Myth: the first biologic you try will be the one you stay on. Some people stay on one drug for years, and others change for loss of response, side effects or coverage. Our guide on switching biologics reviews the cohort data.

Myth: infusion drugs are stronger than injections. Route describes how a drug is given, not how well it works. Adalimumab and ustekinumab, one injected and one started by infusion, had similar results in SEAVUE (Sands 2022).

Myth: biologics are the only thing that matters. Diet, smoking, stress, infections, other medicines and surgery all play a part. Biologics are one tool, and your team decides how they fit with the others.

How was this article put together?

This article was written by the Clairop team, not a clinician, and no doctor has reviewed it. We opened each cited trial abstract and guideline summary, and the US prescribing information on DailyMed, to confirm the figures quoted. Where we could not open a source or find evidence, such as ECCO's detailed recommendations and head-to-head onset speed, we say so instead of filling the gap. It describes evidence and questions, not advice for any individual.

The bottom line

The best biologic for Crohn's disease is the one that fits your disease features, your treatment history, your risk profile and your life, chosen with a gastroenterologist who knows your results. Guidelines and network meta-analyzes give a map of groups, head-to-head trials are few, and Reddit threads give a feel for what daily life on each option can be like. Bring your questions, your symptom log and your test results, and treat the choice as a conversation that can be revisited as your disease and the evidence change.

Frequently asked questions

Which biologic is best for Crohn's disease?
No biologic is best for everyone. The 2025 AGA guideline recommends infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment, and suggests vedolizumab or certolizumab too. The best fit for you depends on prior treatment, perianal disease, safety, route, cost and coverage, so the choice is a shared decision with your gastroenterologist.
Is Stelara or Skyrizi better for Crohn's disease?
In the SEQUENCE trial, people who had stopped responding to or could not tolerate an anti-TNF had clinical remission at week 24 in 58.6% on risankizumab versus 39.5% on ustekinumab, and endoscopic remission at week 48 in 31.8% versus 16.2%. The trial was open label and funded by AbbVie. Whether that matters for you is a question for your gastroenterologist.
Is Humira or Stelara better for Crohn's disease?
In the SEAVUE head-to-head trial of biologic-naive people, clinical remission at week 52 was 65% with ustekinumab and 61% with adalimumab, a difference that was not statistically significant. Both worked well as monotherapy in that population. Real people still respond differently, so a drug that fails one person can work well for another.
What is the safest biologic for Crohn's disease?
No biologic is risk free. Infliximab and adalimumab carry boxed warnings for serious infections and malignancy, and upadacitinib's boxed warning also lists mortality, cardiovascular events and thrombosis. A 2026 claims study of 12,245 people found no statistically significant differences in serious infections, clots or major cardiovascular events across the main advanced therapies, though it was observational.
Which biologic is best for perianal Crohn's disease?
Infliximab has the longest and strongest randomized evidence for fistulas. A 2026 meta-analysis of placebo-controlled trials concluded that infliximab is effective for perianal Crohn's disease, with limited evidence for adalimumab, ustekinumab and upadacitinib, because only 4 of 14 studies were designed for fistulas. Fistulas also need surgical and imaging input, so your team plans the combination.
Does it matter which biologic you try first?
It can. For people new to advanced therapy, the AGA suggests choosing a higher-efficacy option such as infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab or guselkumab over certolizumab pegol or upadacitinib. After a prior anti-TNF, its positioning shifts toward adalimumab, risankizumab, guselkumab or upadacitinib. Your history decides which table applies to you.
Why do insurers make you try certain biologics first?
In the US, plans often use step therapy and prior authorization, which require a preferred, often lower-cost drug or biosimilar before approving another. Rules differ by plan, and your gastroenterologist's office usually files the paperwork. People in r/CrohnsDisease commonly describe this as the biggest driver of which drug they end up on. Ask your team about appeals if a request is denied.
Are biosimilars as good as the original biologic for Crohn's?
In NOR-SWITCH, 26% on continued originator infliximab and 30% on the biosimilar CT-P13 had disease worsening over 52 weeks, within the pre-set non-inferiority margin, and about a third of participants had Crohn's disease. Safety was similar. Whether a biosimilar is right for you is a decision for your prescriber.
How long does it take to know if a biologic is working?
It depends on the drug and how response is measured. Trials check clinical response or remission at set points, such as week 6 for ustekinumab and vedolizumab induction and week 12 for risankizumab and upadacitinib, and endoscopic outcomes later. Your gastroenterologist sets your checkpoint and repeats symptoms, blood markers, stool tests or scopes to judge it.
What is the best way to track whether a Crohn's biologic is working?
Keep a dated log of stool frequency, pain, blood, urgency, energy and side effects against the start date and each dose, and bring it with your blood and calprotectin results. In the CALM trial, adjusting treatment on symptoms plus CRP and calprotectin led to more mucosal healing than symptoms alone. A symptom app such as Clairop can hold that timeline, but it does not replace testing.

Sources

  1. Scott FI, Ananthakrishnan AN, Click B, Agrawal M, Syal G, Haydek JP, et al. AGA living clinical practice guideline on the pharmacologic management of moderate-to-severe Crohn's disease. Gastroenterology. 2025;169(7):1397-448. doi:10.1053/j.gastro.2025.09.038
  2. Singh S, Murad MH, Yuan Y, Ananthakrishnan AN, Click B, Syal G, et al. Comparative efficacy of advanced therapies for management of moderate-to-severe Crohn's disease: 2025 AGA evidence synthesis. Gastroenterology. 2025;169(7):1516-36. doi:10.1053/j.gastro.2025.08.032
  3. Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2025;120(6):1225-64. doi:10.14309/ajg.0000000000003465
  4. Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2024;18(10):1531-55. doi:10.1093/ecco-jcc/jjae091
  5. Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10341):2200-11. doi:10.1016/S0140-6736(22)00688-2
  6. Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease. N Engl J Med. 2024;391(3):213-23. doi:10.1056/NEJMoa2314585
  7. Park SK, Ahuja D, Yeh KH, Patel SB, Goodwin SW, Ma C, et al. Comparative safety of advanced therapies for Crohn disease. JAMA Netw Open. 2026;9(2):e2557922. doi:10.1001/jamanetworkopen.2025.57922
  8. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-21. doi:10.1056/NEJMoa1215739
  9. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946-60. doi:10.1056/NEJMoa1602773
  10. D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015-30. doi:10.1016/S0140-6736(22)00467-6
  11. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031-46. doi:10.1016/S0140-6736(22)00466-4
  12. Loftus EV, Panes J, Lacerda AP, Peyrin-Biroulet L, D'Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388(21):1966-80. doi:10.1056/NEJMoa2212728
  13. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340(18):1398-405. doi:10.1056/NEJM199905063401804
  14. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876-85. doi:10.1056/NEJMoa030815
  15. Yuan Y, Jairath V, Hanzel J, Hupe M, Sedano R, Shehab M, et al. Biologics and small molecules for perianal Crohn's disease: a systematic review and meta-analyses of randomized placebo-controlled trials. Inflamm Bowel Dis. 2026:2193-211. doi:10.1093/ibd/izag099
  16. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-95. doi:10.1056/NEJMoa0904492
  17. Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304-16. doi:10.1016/S0140-6736(17)30068-5
  18. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanasek T, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-89. doi:10.1016/S0140-6736(17)32641-7
  19. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031
  20. Janssen Biotech Inc. REMICADE (infliximab) prescribing information. DailyMed, US National Library of Medicine, published 5 June 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257
  21. AbbVie Inc. HUMIRA (adalimumab) prescribing information. DailyMed, US National Library of Medicine, published 6 February 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d
  22. AbbVie Inc. RINVOQ (upadacitinib) prescribing information. DailyMed, US National Library of Medicine, published 15 July 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095
  23. Celltrion USA Inc. ZYMFENTRA (infliximab-dyyb) prescribing information. DailyMed, US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a193ab-9f96-4da6-aa7c-31212e81879a

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools